Brean Murray Carret & Co. Starts Pharmacyclics (PCYC) at Buy; Positive on Ibrutinib

Brean Murray Carret & Co. initiates coverage on Pharmacyclics (NASDAQ: PCYC) with a Buy. PT $80.00.

Analyst, Brian Skorney, said, "Initiating coverage on PCYC with a Buy primarily based on the value of the first-in-class BTK inhibitor, ibrutinib. We believe ibrutinib is one of the most attractive drugs in development, given the consistently robust clinical activity demostrated in several different hematologic malignancies. The impressive efficacy is matched by an equally impressive safety profile..."

For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.

Shares of Pharmacyclics closed at $34.77 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Canaccord Starts Galiano Gold (GAU:CN) at Buy
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'